1993 UMass Dartmouth, B.S., Chemistry/Biochemistry
1997 Boston University, M.S., Chemistry
1998 Boston University, Ph.D., Chemistry
1998 Massachusetts Institute of Technology, Post-Doctoral Appointment
2014 Project Management Institute, PMP Certification
Daniel DeOliveira’s career in scientific research and drug discovery has its roots at UMass Dartmouth, where he performed graduate-student level research as an undergrad under the guidance of Professor Bal-Ram Singh. This work on the elucidation of complex protein structures under garnered recognition at a national level and publication in a scientific journal. He completed an internship at a Sanofi Pharmaceuticals world headquarters. DeOliveira won awards from the American Association for the Advancement of Science, American Chemical Society, and a Merck Science Award.
DeOliveira earned master’s and doctoral degrees in chemistry from Boston University. His experience at UMassD was beneficial as he began his own research at BU designing novel peptides (mini-proteins) to study the effects on bone and shell growth, and to add to the understanding of bio-mineralization in animals and shellfish. His work was published in the Journal of the American Chemical Society.
DeOliveira was director of the Combinatorial Peptide Core Synthesis Facility at Massachusetts Institute of Technology, working in immunogenicity and HIV research. He later worked as a Senior Scientist at Dyax Corp., a company focused on rare hereditary diseases, where his research and work on peptides contributed to the eventual FDA approval of Kalbitor (Ecallantide, DX-88), a treatment for hereditary angioedema. Following Dyax, he worked at Ipsen Pharmaceuticals directing research programs focused on peptide-based therapeutics. He has over two dozen peer-reviewed publications.
He has gone on to earn his Professional Project Management (PMP) certification, and is now leading two ventures including a thriving consulting business, Life Sciences Project Management, based on peptide therapeutics and investigating rare diseases.